JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
Want to see JP:4552 full AI Analyst Report?
4552 Stock Chart & Stats
¥712.00
-¥21.00(-3.43%)
At close: 4:00 PM EST
¥712.00
-¥21.00(-3.43%)
Day’s Range― - ―
52-Week Range¥445.00 - ¥824.00
Previous CloseN/A
Volume326.50K
Average Volume (3M)578.69K
Market Cap
¥56.43B
Enterprise Value¥100.52B
Total Cash (Recent Filing)¥13.18B
Total Debt (Recent Filing)¥40.10B
Price to Earnings (P/E)25.5
Beta0.88
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.71%
Share Statistics
EPS (TTM)-45.01
Shares Outstanding129,686,310
10 Day Avg. Volume668,090
30 Day Avg. Volume578,686
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)1.48
Price to Sales (P/S)1.72
P/FCF Ratio-5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥564.00Price Target Upside-20.79% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)1.64
Revenue Forecast (FY)¥43.86B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA solid FY2026 revenue rebound indicates recovering demand and stronger product traction after a prior downturn. Sustained top-line recovery supports scale for commercialization and R&D investment over the next 2–6 months, improving the firm's ability to execute strategic plans.
Sizable Equity BaseA meaningful equity cushion provides financial flexibility to absorb operational volatility, fund R&D, and support manufacturing investments without immediate insolvency risk. This structural capital base helps maintain strategic options during cyclical pressure.
Specialty Biologics & Manufacturing CapabilityConcentration in rare-disease biologics and in-house contract manufacturing creates durable competitive advantages: niche therapeutic focus, higher barriers to entry, and diversified revenue streams from manufacturing services that persist beyond short-term market swings.
Bears Say
Negative Operating Cash FlowRepeated negative operating cash flow undermines organic funding for operations and new launches. Over several quarters this forces reliance on external financing, elevates execution and refinancing risk, and constrains the company's ability to sustainably scale commercialization and R&D.
Rising LeverageA sharp rise in debt reduces financial flexibility and increases interest and refinancing burdens. When combined with weak cash generation, higher leverage materially raises default and covenant risks and may divert cash flow from strategic investments to debt servicing.
Volatile ProfitabilityLarge year-to-year swings in profitability signal inconsistent margin sustainability and earnings quality. This volatility complicates long-term planning, weakens predictability of free cash generation, and increases the risk that future investments may not yield anticipated returns.
JCR Pharmaceuticals Co., Ltd. News
4552 FAQ
What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?
JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥445.00 and its highest was ¥824.00 in the past 12 months.
What is JCR Pharmaceuticals Co., Ltd.’s market cap?
JCR Pharmaceuticals Co., Ltd.’s market cap is ¥56.43B.
When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?
JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is Jul 29, 2026 which is in 49 days.
How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?
JCR Pharmaceuticals Co., Ltd. released its earnings results on May 13, 2026. The company reported ¥3.57 earnings per share for the quarter, beating the consensus estimate of -¥6.628 by ¥10.198.
Is JCR Pharmaceuticals Co., Ltd. overvalued?
According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Overvalued.
Does JCR Pharmaceuticals Co., Ltd. pay dividends?
JCR Pharmaceuticals Co., Ltd. pays a Semiannually dividend of ¥9.922 which represents an annual dividend yield of 2.71%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here
What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?
JCR Pharmaceuticals Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?
JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.
What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?
JCR Pharmaceuticals Co., Ltd. reported an EPS of ¥3.57 in its last earnings report, beating expectations of -¥6.628. Following the earnings report the stock price went up 0.896%.
Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingredients within Japan. The company offers a range of therapeutic solutions, including GROWJECT, which addresses growth hormone deficiency and short stature; IZCARGO, prescribed for Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion, utilized in the management of Fabry disease; and TEMCELL HS Inj, employed to treat acute graft-versus-host disease. Beyond its current offerings, JCR Pharmaceuticals is also developing Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended for the treatment of renal anemia. Furthermore, the company markets various medical devices and laboratory instruments. Founded in 1975, its headquarters are situated in Ashiya, Japan.
4552 Stock 12 Month Forecast
Average Price Target
¥564.00
▼(-20.79% Downside)
Technical Analysis
Kyowa Kirin Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---